AbbVie Sues US Government Over Botox Inclusion in Medicare Price Negotiations

AbbVie has filed a lawsuit against the US Department of Health and Human Services (HHS) to challenge the inclusion of its blockbuster drug, Botox, in Medicare's price negotiation program. The pharmaceutical giant argues that Botox should be exempt from the program under the Inflation Reduction Act (IRA) because it is a plasma-derived product. The lawsuit specifically targets the authority of the Centers for Medicare & Medicaid Services (CMS), alleging violations of administrative law and the First Amendment. This legal action comes as the US government seeks to lower healthcare costs by negotiating prices for high-expenditure drugs. Botox represents a significant revenue stream for AbbVie, and its inclusion in the program could impact the company's future profit margins. Investors are closely monitoring the case as it reflects broader regulatory pressures facing the pharmaceutical industry.